Induction of IgE responses using a recombinant mosquito salivary allergen rAed a 2 without adjuvant in mice. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Induction of IgE responses using a recombinant mosquito salivary allergen rAed a 2 without adjuvant in mice.

Int Arch Allergy Immunol. 1999 Oct;120(2):135-40. Unique Identifier : AIDSLINE MED/20014682
Wang H; Mao X; Simons FE; Peng Z; Section of Allergy and Clinical Immunology, Department of; Pediatrics and Child Health, Winnipeg, Canada.


Abstract: BACKGROUND: Reactions to mosquito bites are a global problem. Several salivary proteins from Aedes (Ae.) aegypti, the most common mosquito species, have been cloned and expressed. Plasmid DNA vaccination has been shown to be effective in the downregulation of IgE responses. To investigate the in vivo antigenicity of these recombinant proteins and to study the mechanisms underlying plasmid DNA vaccination, a mouse model sensitized with a recombinant antigen has been developed. METHODS: BALB/c and C57BL/6 mice were injected intradermally with a 37-kD recombinant Ae. aegypti salivary allergen (rAed a 2) in the absence of adjuvant twice weekly for 8 weeks and then challenged twice with rAed a 2 at weeks 10 and 12. Serum rAed a 2-specific IgE, IgG1 and IgG2a were measured by ELISA. Intradermal tests were performed every 4 weeks. The binding capacity of rAed a 2-specific IgE to the native Aed a 2 was examined by immunoblotting. RESULTS: In both strains, sensitization with rAed a 2 induced a significant increase in IgE and IgG1, but not IgG2a. In all sensitized mice, a positive immediate skin reaction was apparent, while delayed-type hypersensitivity reactions were not observed. BALB/c mice produced significantly higher levels of IgE and IgG1 and larger wheals than C57BL/6 mice. The IgE antibodies elicited by rAed a 2 bound to not only rAed a 2 but also its natural form in mosquito saliva. CONCLUSION: (1) Repeated injections of rAed a 2 without adjuvant induce predominant Th2-type responses in mice. (2) BALB/c mice are better responders for IgE production than C57BL/6 mice. (3) rAed a 2 has identical allergenicity to its natural form.


Keywords: JOURNAL ARTICLE Adjuvants, Immunologic/ADMINISTRATION & DOSAGE Aedes/*IMMUNOLOGY Allergens/IMMUNOLOGY Animal Blotting, Western Dose-Response Relationship, Immunologic Epitopes Female IgE/IMMUNOLOGY Insect Bites and Stings/IMMUNOLOGY Insect Proteins/*IMMUNOLOGY Mice Mice, Inbred BALB C Mice, Inbred C57BL Recombinant Proteins/IMMUNOLOGY Salivary Proteins/*IMMUNOLOGY Skin Tests Support, Non-U.S. Gov't Th2 Cells/IMMUNOLOGY

KWDjournalarticleadjuvants,immunologic/administration&dosageaedes/KWDimmunologyallergens/immunologyanimalblotting,westerndose-responserelationship,immunologicepitopesfemaleige/immunologyinsectbitesandstings/immunologyinsectproteins/KWDimmunologymicemice,inbredbalbcmice,inbredc57blrecombinantproteins/immunologysalivaryproteins/KWDimmunologyskintestssupport,non-uKWDsKWDgov'tth2cells/immunology
000330
A0030873


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .